Advertisement

Topics

ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer

04:18 EDT 10 Sep 2017 | ecancermedicalscience

Mature results from the KEYNOTE-045 trial presented at the ESMO 2017 Congress in Madrid have confirmed significantly longer survival in patients with advanced urothelial cancer who receive the checkpoint inhibitor pembrolizumab after initial chemotherapy,...

Original Article: ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer

NEXT ARTICLE

More From BioPortfolio on "ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer"

Quick Search
Advertisement
 

Relevant Topic

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...